P752: TARGETING S100A9 IN THE MYELODYSPLASTIC INFLAMMATORY BONE MARROW MICROENVIRONMENT BY TASQUINIMOD IMPROVES THE SUPPORTIVE FUNCTION OF MESENCHYMAL STROMAL CELLS
Main Authors: | M. Wobus, E. Balaian, M. Lissner, R. Towers, U. Oelschlägel, R. Wehner, T. Chavakis, M. Törngren, H. Eriksson, E. Bondesson, U. Platzbecker, M. Bornhäuser, K. Sockel |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000845892.14907.80 |
Similar Items
-
P725: METABOLIC PROPERTIES OF MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROMES
by: E. Balaian, et al.
Published: (2022-06-01) -
Myelodysplastic Syndromes and Metabolism
by: Ekaterina Balaian, et al.
Published: (2021-10-01) -
Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes
by: Amanpreet Kaur Bains, et al.
Published: (2022-09-01) -
Tasquinimod targets suppressive myeloid cells in the tumor microenvironment
by: Li Shen, et al.
Published: (2019-10-01) -
A review of tasquinimod in the treatment of advanced prostate cancer
by: Williamson SC, et al.
Published: (2013-03-01)